On the one hand, in the ESCC TME, IL-17 can recruit beneficial neutrophils, CD8+ T lymphocytes and B lymphocytes to inhibit tumor growth (Chen et al., 2017; Lu et al., 2016). This evidence concerns the gene IL17A and neoplasm.